Abstract
The first event in the initiation of an immune response is the capture and presentation of antigen to T cells. Such presentation involves two distinct steps: (1) display of the antigen, which requires uptake, processing and re-expression of the antigen in association with MHC molecules on the presenting cell surface; and (2) triggering, in which the presenting cell provides signals leading to the activation of the responding T cell. Two sorts of cells can capture antigens, the 'professional' antigen-presenting cells (APCs) such as dendritic cells and macrophages, and the B cells. Both types of cells can display antigens and the APCs are known to be able to trigger resting T cells. But despite in vitro evidence that certain B-cell types can reactivate previously-activated T cells1–6, it is not yet clear whether a B cell can initiate an immune response by providing the signals necessary to activate a resting T cell. We reasoned that resting B cells should not have this capacity because of the problems this would present with tolerance to self idiotypes. By exploiting the unique properties of the avian haematopoietic system, we have examined the presenting capacity of B cells in vivo and found that resting B cells are indeed unable to activate resting T cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chesnut, R. W. & Grey, H. M. Adv. Immun. 39, 51–92 (1986).
Rock, K. L., Benacerraf, B. & Abbas, A. K. J. exp. Med. 160, 1102–1113 (1984).
Ashwell, J. D., De Franco, A. L., Paul, W. E. & Schwartz, R. H. J. exp. Med. 159, 881–905 (1984).
Lanzavecchia, A. Nature 314, 537–539 (1985).
Tony, H. B. & Parker, D. C. J. exp. Med. 161, 223–241 (1985).
Ron, Y. & Sprent, J. J. Immun. 138, 2848–2856 (1987).
Toivanen, P., Toivanen, A. & Sorvari, T. Proc. natn. Acad. Sci. U.S.A. 71, 957–962 (1974).
Vainio, O., Koch, C. & Toivanen, A. Immunogenetics 19, 131–139 (1984).
Pink, J. R. L. & Lassila, O. Curr. Topics Microbiol. Immun. 135, 57–64 (1987).
Lehtonen, L., Vainio, O., Eerola, E. & Toivanen, P. Transplantation 40, 398–405 (1985).
Pink, J. R. L., Droege, W., Hála, K., Miggiano, V. C. & Ziegler, A. Immunogenetics 5, 203–216 (1977).
Briles, W. E. et al. Immunogenetics 15, 441–450 (1982).
Gronowitz, E., Coutinho, A. & Melchers, F. Eur. J. Immun. 6, 588–590 (1976).
Matzinger, P. Nature 292, 497–501 (1981).
Goverman, J., Hunkapillar, T. & Hood, L. Cell 45, 475–484 (1986).
Bevan, M. J. Nature 269, 417–419 (1977).
Zinkernagel, R. M. et al. J. exp. Med. 147, 882–896 (1978).
Heber-Katz, E. & Wilson, D. B. J. exp. Med. 142, 928–935 (1975).
Waldmann, H., Pope, H., Brent, L. & Bighouse, K. Nature 274, 166–168 (1978).
Matzinger, P. & Mirkwood, G. J. exp. Med. 148, 84–92 (1978).
Wagner, H., Hardt, C., Stockinger, H., Pfizenmeier, K., Bartlett, R. & Röllinghof, M. Immun. Rev. 58, 95–129 (1981).
Katz, D. H. Transplantn Rev. 12, 141–179 (1972).
Swain, S. L. & Dutton, R. W. J. Immun. 118, 2262–2268 (1977).
Rabellino, E., Colon, S., Grey, H. M. & Unanue, E. R. J. exp. Med. 133, 156–167 (1971).
Andersson, J., Lafleur, L. & Melchers, F. Eur. J. Immun. 4, 170–180 (1974).
Bikoff, E. & Birshtein, B. K. J. Immun. 137, 28–34 (1986).
Bogen, B., Malissen, B. & Haas, W. Eur. J. Immun. 16, 1373–1380 (1986).
Bogen, B. & Weiss, S. Proc. Germinal Center Conference, (Plenum Press, New York, in the press.)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lassila, O., Vainio, O. & Matzinger, P. Can B cells turn on virgin T cells?. Nature 334, 253–255 (1988). https://doi.org/10.1038/334253a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/334253a0
This article is cited by
-
Nanocarriers Targeting Dendritic Cells for Pulmonary Vaccine Delivery
Pharmaceutical Research (2013)
-
Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence
Molecular Therapy (2012)
-
Cross-primed CD8+ T cells mediate graft rejection via a distinct effector pathway
Nature Immunology (2002)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.